A Randomized, Open-Label, Parallel-Arm Study to Assess the Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab (BIIB037) in Healthy Subjects Compared to a Single, Weight-Based Intravenous Dose
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2017
At a glance
- Drugs Aducanumab (Primary) ; Aducanumab (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Biogen
- 12 Jan 2017 Status changed from active, no longer recruiting to completed.
- 13 Oct 2016 Planned End Date changed from 1 Sep 2016 to 1 Nov 2016.
- 13 Oct 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Nov 2016.